|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:amoebic_dysentery
|
|
gptkbp:activities
|
inhibits nucleic acid synthesis
|
|
gptkbp:appointed_by
|
intravenous infusion
oral tablet
|
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tindamax
|
|
gptkbp:clinical_trial
|
Phase III
infections caused by anaerobic bacteria
infections caused by protozoa
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
metronidazole
disulfiram
|
|
gptkbp:developed_by
|
gptkb:Sanofi
|
|
gptkbp:dosage_form
|
gptkb:tablet
suspension
|
|
gptkbp:duration
|
1 to 5 days
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tinidazole
|
|
gptkbp:ingredients
|
C7 H13 N3 O4 S
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:warfarin
lithium
|
|
gptkbp:is_atype_of
|
P01 A B02
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_part_of
|
nitroimidazole class
|
|
gptkbp:is_used_for
|
treating bacterial infections
treating protozoal infections
|
|
gptkbp:lifespan
|
12 to 14 hours
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:safety_features
|
Category B
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
allergic reactions
seizures
liver toxicity
neuropathy
metallic taste
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:suitable_for
|
children under 3 years
|
|
gptkbp:treatment
|
giardiasis
trichomoniasis
amebiasis
|
|
gptkbp:type_of
|
19387-91-0
|